Ally Bridge Group’s Vor Biopharma VOR Stock Holding History

Ally Bridge Group’s Portfolio VOR Stock Details VOR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-12,758	Closed	-$1.02M	–	40
2022 Q3	$1.02M	Buy	+12,758	New	+$1.25M	0.67%	32

Other funds holding VOR

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Ally Bridge Group's VOR Position: Q4 2022 in Review

Ally Bridge Group sold out of Vor Biopharma (VOR) in Q4 2022, closing a stake of 12,758 shares — an estimated $1.02M sold.

Ally Bridge Group first reported a position in VOR in Q3 2022 and held it in 1 quarter. The position peaked at $1.02M in Q3 2022. 58 funds tracked by Wall St. Rank hold VOR as of Q4 2022.

Ally Bridge Group reported no remaining Vor Biopharma position as of Q4 2022 after selling out during the quarter.
Ally Bridge Group sold 12,758 Vor Biopharma shares in Q4 2022, an estimated $1.02M.
Ally Bridge Group first reported a position in Vor Biopharma in Q3 2022 and held it in 1 quarter.
Ally Bridge Group's Vor Biopharma position peaked at $1.02M in Q3 2022.
58 funds tracked by Wall St. Rank held Vor Biopharma as of Q4 2022.

Based on Ally Bridge Group's 13F filing for Q4 2022, filed 14 Feb 2023.